Steven Gannon
Director/Board Member at XENON PHARMACEUTICALS INC.
Net worth: 1 M $ as of 31/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ian Mortimer | M | 48 | 11 years | |
| Anthony Cheung | M | 53 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | - |
| Simon Pimstone | M | 56 | 28 years | |
| Jason Hanson | M | 55 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 6 years |
| John Valliant | M | 54 | 10 years | |
| Timothy J. Keiffer | M | - |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 25 years |
| Dawn Svoronos | F | 70 | 8 years | |
| Jodi Regts | F | - | 9 years | |
| Alexander Nichols | M | 38 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 2 years |
| Amanda Cray | F | - | - | |
| Elizabeth Garofalo | M | 66 | 3 years | |
| Sherry Aulin | F | 40 | 13 years | |
| Andrea DiFabio | F | 55 | 2 years | |
| Philina Lee | M | 47 | 3 years | |
| Pablo Cagnoni | M | 60 | 5 years | |
| Donald Bergstrom | M | 52 | 3 years | |
| Richard Glickman | M | 65 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 13 years |
| Clarence Machado | M | 60 | 4 years | |
| Gary Patou | M | 65 | 20 years | |
| Barbara Duncan | F | 59 | 4 years | |
| Mohammad Azab | M | 68 | 21 years | |
| Mohit Rawat | M | - | 3 years | |
| Teresa Bitetti | F | - | 1 years | |
| Rachel Levine | F | - | 8 years | |
| Michael Rogawski | M | - | - | |
| Marie-Hélène Raigneau | F | - |
Altasciences Co., Inc.
 Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Altasciences Co., Inc. engages in the provision of clinical pharmacology development services. It offers bioanalysis and research services, preclinical services, clinical services, and development programs. The company was founded in 1992 and is headquartered in Laval, Canada. | - |
| Frédéric Collet | M | - | 6 years | |
| Cara Ferreira | M | - | 4 years | |
| Germo Gericke | M | - | 6 years | |
| Katherine Betz-Doherty | F | - | 6 years | |
| Chris von Seggern | M | - | 4 years | |
| Gillian Cannon | M | 60 | 1 years | |
| Christopher Kenney | M | - | 3 years | |
| Jessica Toepfer | F | - | 6 years | |
| David Meek | M | 59 | 1 years | |
| James Empfield | M | - | 8 years | |
| Marco Boorsma | M | 49 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | - |
| Justin Gover | M | 53 | 1 years | |
| Gerry Brunk | M | 55 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | - |
| Nancy Lurker | F | 66 |
Altasciences Co., Inc.
Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Altasciences Co., Inc. engages in the provision of clinical pharmacology development services. It offers bioanalysis and research services, preclinical services, clinical services, and development programs. The company was founded in 1992 and is headquartered in Laval, Canada. | 3 years |
| Christopher Leamon | M | 57 | 3 years | |
| Eric S. Hoffman | M | 54 | 3 years | |
| Ashley Friedman | M | 46 |
Altasciences Co., Inc.
Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Altasciences Co., Inc. engages in the provision of clinical pharmacology development services. It offers bioanalysis and research services, preclinical services, clinical services, and development programs. The company was founded in 1992 and is headquartered in Laval, Canada. | 3 years |
| Sheila M. Grant | F | - | 4 years | |
| Christopher J. Perkin | M | - |
Altasciences Co., Inc.
Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Altasciences Co., Inc. engages in the provision of clinical pharmacology development services. It offers bioanalysis and research services, preclinical services, clinical services, and development programs. The company was founded in 1992 and is headquartered in Laval, Canada. | 14 years |
| Shelley McCloskey | F | 64 | 5 years | |
| Beatrice Setnik | M | - |
Altasciences Co., Inc.
Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Altasciences Co., Inc. engages in the provision of clinical pharmacology development services. It offers bioanalysis and research services, preclinical services, clinical services, and development programs. The company was founded in 1992 and is headquartered in Laval, Canada. | 5 years |
| Maria D. Stahl | F | 53 | 4 years | |
| Eric Burak | M | - | 7 years | |
| Andrei Vladimirovich Petrov | M | 50 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 9 years |
| Robin Sherrington | M | 63 | 23 years | |
| Jeremy Bender | M | 52 | 1 years | |
| Dennis Langer | M | 73 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 9 years |
| Steve Mason | M | - |
Altasciences Co., Inc.
Altasciences Co., Inc. Miscellaneous Commercial ServicesCommercial Services Altasciences Co., Inc. engages in the provision of clinical pharmacology development services. It offers bioanalysis and research services, preclinical services, clinical services, and development programs. The company was founded in 1992 and is headquartered in Laval, Canada. | - |
| John Crowley | M | 51 | 5 years | |
| Dmitri Bobilev | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Holler | M | 67 | 25 years | |
| Michael Hayden | M | 72 | 26 years | |
| Stefano Buono | M | 57 | 16 years | |
| Gérard Ber | M | 66 | 16 years | |
| Heinz Christoph Mäusli | M | 61 | 15 years | |
| George T. Dory | M | 54 |
Concordia University
| 7 years |
| Robert G. Moussa | M | 77 |
Mallinckrodt Medical, Inc.
 Mallinckrodt Medical, Inc. Medical SpecialtiesHealth Technology Mallinckrodt Medical, Inc. manufactures and markets healthcare products. Its products include contrast media & delivery systems, radiology imaging products, radiopharmaceuticals and urology imaging systems. The company is headquartered in Pointe-Claire, Canada. | 4 years |
| Susanne Antonie Schaffert | M | 57 | 1 years | |
| Y. Paul Goldberg | M | 64 | 18 years | |
| Richard G. DeVleeschouwer | M | 67 |
Aptalis Pharma LLC
 Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL. | - |
| Kapil Dhingra | M | 64 | 4 years | |
| Christine Cvijic | F | 46 | 1 years | |
| Christopher Neuman | M | - |
Concordia University
| 8 years |
| Muriel de Szilbereky | F | 72 | 3 years | |
| Christine Mikail, | - | - | 1 years | |
| Eric Hsu | M | - |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 16 years |
| Tan Cheng Loke | M | - |
Concordia University
| 6 years |
| Theresa Maria Stevens | F | 63 |
Aptalis Pharma LLC
Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL. | 5 years |
| Yvonne Greenstreet | M | 61 | - | |
| Edward Sturchio | M | - | 2 years | |
| Chau Khuong | M | 48 | 4 years | |
| Francois Nader | M | 67 | 2 years | |
| Michael M. Tarnow | M | 79 | 22 years | |
| Christian Merle | M | 70 | - | |
| Richard Scheller | M | 70 | 5 years | |
| Clarissa Desjardins | M | 57 | - | |
| Heather Elizabeth Preston | M | 58 | 4 years | |
| Gerald P. McDole | M | 84 |
AstraZeneca Canada, Inc.
 AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | 4 years |
| Karen G. Corraini | F | 69 | 14 years | |
| Johan Rutger Christenson | M | 65 | 6 years | |
| Richard E. Maroun | M | 69 |
Aptalis Pharma LLC
Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL. | 2 years |
| Leopoldo Giampaolo Zambeletti | M | 55 | - | |
| Luigi Lo Basso | M | - |
Concordia University
| 2 years |
| Lynn Wick | F | - | 4 years | |
| Jim McMullan | M | - |
Concordia University
| 3 years |
| Chi Ping Chow | M | 66 |
Concordia University
| 4 years |
| Marc Rivet | M | - |
Concordia University
| 3 years |
| Victor Cantore | M | 58 |
Concordia University
| 4 years |
| Marc Léger | M | 65 |
Concordia University
| 4 years |
| Mohammed bin Ali Al-Hokali | M | - |
Concordia University
| 4 years |
| Serge Paiement | M | - |
Concordia University
| 4 years |
| Douglas Wight | M | - |
Concordia University
| 4 years |
| Michael McLaughlin | M | - |
Concordia University
| 4 years |
| Elizabeth Eastland | M | - |
Concordia University
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 79 | 79.00% |
| France | 18 | 18.00% |
| United States | 3 | 3.00% |
| Ireland | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Steven Gannon
- Personal Network